ICE Bioscience

ICE Bioscience Inc., established in 2010, focuses on in vitro drug screening technologies based on cells and biochemistry from the lead compound screening, optimization to the preclinical candidate molecule stage, as well as early drug mechanism research. It emphasizes biological and pharmacological research technologies in the fields of oncology, immunology, cardiovascular, and central nervous system diseases, positioning itself as an innovative CRO+ explorer. ICE Bioscience pays attention to the needs of new drug development companies for speed, efficiency, and results, helping customers improve the efficiency of new drug R&D with professional technology and efficient communication. ICE Bioscience is committed to building a comprehensive target screening and in vitro biology research platform, establishing a series of research technology clusters based on biology and pharmacology, providing customers with new drug R&D services covering various targets and disease areas, including active compound discovery, target validation, lead compound optimization, and selection of preclinical candidate drugs. The company has established over 100 ion channel, 100 GPCR, 800 enzymatic targets, and 40 nuclear receptor screening cell lines and validation methods, covering most druggable targets and holding a leading position and competitive advantage in China. The company has built platforms such as protein purification, biochemical enzymology, tumor cytology, immunology, electrophysiology, cardiac ex vivo research, CNS pharmacology, drug off-target effect screening, drug cardiac safety evaluation, and ADME, comprehensively supporting the DMTA (Design, Make, Test, Analyze) integrated service for innovative drug R&D. ICE Bioscience serves more than 600 new drug R&D institutions in China and has received widespread acclaim from customers.